Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMX-110 + Tislelizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMX-110 | IMX110|IMX 110 | IMX-110 is a nanoparticle formulation of curcumin and doxorubicin, which may decrease tumor cell growth and induce tumor cell apoptosis (NCI Drug Dictionary). | ||
Tislelizumab | Tevimbra | BGB-A317|tislelizumab-jsgr | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Tevimbra (tislelizumab) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). Tevimbra (tislelizumab) is FDA-approved for use in patients with unresectable or metastatic esophageal squamous cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05840835 | Phase Ib/II | IMX-110 + Tislelizumab | Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (IMMINENT-01) | Recruiting | BRA | 0 |